title: Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsonian flatworm model.
abstract: It has been known that rotenone and 1-methyl-4-phenylpyridinium ion (MPP(+), a metabolite of MPTP), which inhibit mitochondrial complex I, are useful tools for parkinsonian models in vertebrates such as primates and rodents. Planarian, an invertebrate flatworm, has a high potential for regeneration, and dopamine plays a key role in its behavior. In the present study, we examined a cloned planarian, the GI strain from Dugesia japonica. Planarians that were treated with rotenone or MPTP underwent autolysis and individual death in a concentration- and time-dependent manner. In addition, these effects induced by rotenone or MPTP were inhibited by several antiparkinsonian drugs and caspase inhibitors. These results suggest that the degeneration of planarian dopaminergic system induced by rotenone or MPTP may be mediated through caspase-like activation.
authors.affiliation: Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, Japan. yo-kita@mb.kyoto-phu.ac.jp
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Inden
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Sanada
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Takata
authors.forename: Takashi
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Shun
authors.initials: S
authors.lastname: Shimohama
authors.forename: Hidehumi
authors.initials: H
authors.lastname: Orii
authors.forename: Makoto
authors.initials: M
authors.lastname: Mochii
authors.forename: Kiyokazu
authors.initials: K
authors.lastname: Agata
authors.forename: Kenji
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000201:enzymology; D010932:Planarians / Q000187:drug effects / Q000201:enzymology; D010986:Platyhelminths / Q000187:drug effects* / Q000201:enzymology
chemical_list: D000978:Antiparkinson Agents; D061945:Caspase Inhibitors; D004791:Enzyme Inhibitors; D020169:Caspases